MarketInOut Stock Screener Log In | Sign Up
 

4basebio Plc

LSE • Healthcare • Biotechnology • Quote as of 09/22/2026 16:56
4basebio Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization74.33 mln
Float5.74 mln
Earnings Date09/25/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2
Caution advised

Relative Strength

97 / 100
Top performer

Debt / Equity

1.65
High leverage

Pre-Tax Margin

-1,040%
Severely loss-making

ROE

-91.42
Deeply negative

Business Description

Founded in 2008 and headquartered in Cambridge, UK, 4basebio PLC develops and manufactures advanced DNA and RNA materials used in gene therapies, vaccines, and genome editing applications. The company produces a range of specialized synthetic DNA products designed for different scientific and medical purposes, along with a proprietary delivery platform called Hermes that transports genetic and protein materials without relying on traditional fat-based systems. 4basebio serves customers across Europe, the United States, and other international markets.

Key Fundamentals

EPS-109
ROE-91.42
RPS0.11
ROIC-160
ROA-45.63
Interest Cover-18.86
EBITDA, mln-15.57
EV / EBITDA-4.65
EV / EBIT-4.34
Revenue, mln1.69
EV / Revenue42.81

Quote Details

Last 562.50
Change 7.5 (1.35%)
Open 562.50
Volume 3,442
Turnover 1,936,125
Average Volume 1,490.71

Financial Ratios

Pre-Tax Profit Margin-1,040
Leverage Ratio2.92
Current Ratio7.31
Price / Book7.27
Price / Tangible Book13.97
Debt / Equity1.65
Price / Sales43.58

Financial Strength

Altman Z-Score-1.45
Piotroski F-Score 3 / 9
Beneish M-Score-2

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 12% 97 / 100   
1 Month 17.19% 97 / 100   
2 Months 12.28% 87 / 100   
6 Months 8.8% 48 / 100   
1 Year -29.69% 8 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us